Skip to main content
TTRX
NASDAQ Life Sciences

Turn Therapeutics Registers 25.4M Shares for Resale Under $85M GEM Equity Line

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$8.55
Mkt Cap
$261.397M
52W Low
$2.57
52W High
$16.45
52W Position info
233% above low
Off High info
48% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

TTRX has more than doubled off its 52-week low of $2.57.

Summary

Turn Therapeutics registered up to 25,362,950 shares for resale under its $85.0M GEM equity line — about 83% of shares outstanding — and disclosed it has already drawn roughly $4.07M plus a second ~$2.72M draw-down.


Key Events · Financing and Capital Events · TTRX

  • 25.4M Shares Registered for Resale

    Selling stockholders may resell up to 25,362,950 shares, about 82.96% of the 30,572,704 shares outstanding as of November 6, 2026.

  • GEM Equity Line Terms Quantified

    GEM committed up to $85.0M, buying at 90% of the 15-day average closing price with a $1.00 floor; draw-downs are capped at 300% of average daily volume and GEM at 9.99% ownership.

  • Draw-Downs Already Underway

    1,235,200 shares sold to GEM for about $4.07M at roughly $3.29 per share, and a second notice on October 29, 2026 for 272,642 shares with about $2.72M advanced; roughly $75.0M remains available.

  • Company Gets No Resale Proceeds

    Turn receives nothing from selling-stockholder sales; cash comes only from new share sales to GEM, earmarked for working capital and general corporate purposes.


Analysis · TTRX · Life Sciences

The GEM committed equity line becomes tradable with this prospectus: selling stockholders may resell up to 25,362,950 shares — roughly 83% of the 30.57M shares outstanding — while the company can draw up to $85.0M from GEM at 90% of the 15-day average price, subject to a $1.00 floor. That is a persistent dilution overhang rather than a one-time raise, and it matters most because the company is burning cash with a going-concern warning and only $10.4M of cash. Already the line is in use: 1,235,200 shares sold for about $4.07M at roughly $3.29 each, plus a second draw-down for 272,642 shares with about $2.72M advanced on October 29, 2026. Resales generate no proceeds for the company; cash arrives only when it elects to sell new shares to GEM.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TTRX was trading at $8.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $261.4M. The 52-week trading range was $2.57 to $16.45. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TTRX - Latest Insights

TTRX
Nov 10, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.79
Real-time Price: $8.55 info
Change: -$1.24 (-13%) info
Market Cap: $261.397M info
TTRX
Nov 09, 2026, 8:05 AM EST
Filing Type: S-3
Importance Score:
7
Price at Filing: $9.48
Real-time Price: $8.55 info
Change: -$0.930 (-10%) info
Market Cap: $261.397M info
TTRX
Nov 09, 2026, 8:00 AM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $9.48
Real-time Price: $8.55 info
Change: -$0.930 (-10%) info
Market Cap: $261.397M info
TTRX
Nov 09, 2026, 7:02 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.48
Real-time Price: $8.55 info
Change: -$0.930 (-10%) info
Market Cap: $261.397M info
TTRX
Nov 09, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.48
Real-time Price: $8.55 info
Change: -$0.930 (-10%) info
Market Cap: $261.397M info